Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation (LADR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00135798
Recruitment Status : Completed
First Posted : August 26, 2005
Results First Posted : April 4, 2013
Last Update Posted : April 23, 2013
Sponsor:
Collaborators:
Schering-Plough
Ortho Biotech Clinical Affairs, L.L.C.
Information provided by (Responsible Party):
Averell Sherker, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Tracking Information
First Submitted Date  ICMJE August 24, 2005
First Posted Date  ICMJE August 26, 2005
Results First Submitted Date  ICMJE June 13, 2012
Results First Posted Date  ICMJE April 4, 2013
Last Update Posted Date April 23, 2013
Study Start Date  ICMJE September 2005
Actual Primary Completion Date December 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 22, 2013)
  • Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant: Intent-to-Treat Analysis (ITT) [ Time Frame: 3 months post-transplant ]
    Post-transplant virologic response (pTVR) defined as undetectable HCV RNA at week 12 after liver transplantation.
  • Patients Who Are Negative for HCV RNA at 3 Months Post-transplant: Per-Protocol Analysis (PP) [ Time Frame: 3 months post-transplant ]
    Post-transplant virologic response (pTVR) defined as undetectable HCV RNA at week 12 after liver transplantation, analysed among patients who received treatment.
Original Primary Outcome Measures  ICMJE
 (submitted: August 25, 2005)
• Percentage of patients who are negative for HCV RNA at 3 months post-transplant
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 22, 2013)
  • Patients With Combined Virologic Response (CVR): Intent-to-Treat Analyses (ITT) [ Time Frame: Pre-transplant and 3 months post-transplant ]
    Intent-to-Treat (ITT) analyses of all patients. Combined Virologic Response (CVR), which includes both sustained virologic response pre-transplant (SVR) and post-transplant virologic response (pTVR)
  • Patients With Combined Virologic Response (CVR): Per-Protocol Analysis (PP) [ Time Frame: Pre-transplant and 3 months post-transplant ]
    Per-Protocol (PP) analyses of all patients. Combined Virologic Response (CVR)includes both sustained virologic response pre-transplant (SVR) and post-transplant virologic response (pTVR), analysed among patients who received treatment.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 25, 2005)
  • • Post-Transplant
  •  Percentage of patients who are negative for HCV RNA at 6 and 12 months post-transplant
  •  AST, ALT, alkaline phosphatase, bilirubin, albumin, and prothrombin time at 3, 6, and 12 months
  •  Percentage of patients with histologic recurrence of hepatitis C at 3 and 12 months
  •  Probability of 1 year Graft Survival
  •  Probability of 1 year Patient Survival
  •  Percentage of patients with treated episodes of histologically confirmed rejection
  • -Percentage of patients with treated infections
  • • Pre-Transplant
  •  Percentage of patients who are negative for HCV RNA on the day of transplantation
  •  CBC, AST, ALT, alkaline phosphatase, bilirubin, albumin, prothrombin time every 3 months up to the time of transplant or completion of 48 weeks of therapy
  •  Cumulative doses of peginterferon and ribavirin
  •  Percentage of patients who discontinue either or both antiviral drugs
  •  Percentage of patients who require erythropoietin analogue, G-CSF, or both.
  •  Percentage of patients experiencing cytopenias, adverse events, serious adverse events, or death
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
Official Title  ICMJE The Adult-to-adult Living Donor Liver Transplantation Cohort Study (A2ALL) Low Accelerated Dosing Regimen (LADR) Protocol: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C Virus (HCV) After Liver Transplantation
Brief Summary The purpose of this study is to learn if pre-liver transplant treatment, using peginterferon plus ribavirin, will clear hepatitis C virus (HCV) RNA from the blood in HCV-infected recipients and reduce the risk of recurrent HCV and allograft hepatitis following liver transplant.
Detailed Description

Patients awaiting deceased donor liver transplant will be asked to enroll in this protocol at the time of identification of a potential living liver donor (see note note at end of description). Patients randomized to treatment arm will be encouraged to delay living donor liver transplant (LDLT) until they have received 12 weeks of treatment to allow for a treatment response, if any, to occur. The pros and cons of immediate versus delayed LDLT will be discussed with each patient; the timing of LDLT for patients randomized to no treatment will be determined by clinical need. There will be separate treatment strategies depending upon HCV genotype. Preliminary data and experience strongly suggests that interferon-based treatment clears HCV RNA in the majority of patients with genotypes 2 and 3, even at lower than standard doses (79% on-treatment response and 50% SVR). In contrast, clearance rates for genotype 1 patients with advanced cirrhosis may only be 28% on-treatment with an 11% SVR. In addition, treatment may be associated with significant side effects, intolerance, and increased risk of complications of liver disease. The HCV Committee for A2ALL strongly agreed that monitoring safety of pre-transplant antiviral therapy was essential and advised inclusion of an untreated control group. For these reasons, all patients with HCV, genotypes 1, 4, 5, & 6 infection will be randomized 2:1 to either treatment or control (no treatment). Randomization will be web-based to avoid prior knowledge of treatment assignment at any site. In contrast to the randomized design for patients with genotypes 1, 4, 5, and 6, all patients with genotypes 2 and 3 HCV will receive treatment. All genotypes will be included in the analysis of safety, tolerance, and complications occurring during pre-transplant treatment.

Treatment is continued up to the time of LDLT or deceased donor liver transplant (DDLT), or to a maximum of 48 weeks of continuous treatment. Both peginterferon and ribavirin will be stopped if transplantation is expected to occur within 24 hours. Patients whose liver disease stabilize and are no longer in need of a liver transplant will complete a full 48 weeks of treatment with the aim of achieving SVR. These patients will be followed by measurement of HCV RNA, biochemical tests, hematology, and clinical evaluation at 3, 6, and 12 months post-treatment. If relapse occurs when treatment is discontinued after 48 weeks of therapy, institution of retreatment will be at the discretion of the investigator.

Deferral of LDLT while antiviral therapy is continued will be considered in patients who have undetectable HCV RNA, tolerate treatment well, lack evidence of HCC or ongoing hepatic decompensation, and have had stabilization or improvement in clinical or biochemical measures of liver disease: Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores. These patients should lack uncontrolled or ongoing bleeding from portal hypertension, ascites, systolic blood pressure (SBP), or encephalopathy. The decision to defer transplantation and to continue antiviral therapy will be made at the transplant center by the clinical investigator in consultation with the patient.

Based upon the kinetics of early virologic response in the peginterferon + ribavirin clinical trials, the researchers anticipate that a minimum of 12 weeks treatment is necessary to achieve a virologic response. However, the optimum duration of pre-transplant antiviral therapy that yields the highest rates of prevention of post-transplant HCV recurrence is unknown. Prolongation of antiviral therapy beyond 12 weeks may be advantageous in this regard, but prolonged therapy may also increase the risk of development of intercurrent complications of liver disease or side effects of treatment. In addition, patients with stable liver disease who achieve virologic remission may experience hepatic improvement and avoid transplantation.

All patients, treated and untreated controls will be followed and tested at the same intervals unless specified. Unscheduled visits and additional tests may be performed if clinically indicated, the findings at these visits and results of additional tests will be recorded in the database. The following details the schedule of visits and the tests/procedures to be performed at each visit:

Baseline

  • History and Physical Examination
  • Vital signs: Weight, blood pressure (BP), heart rate (HR), Temperature
  • Fundoscopic exam in all patients. In patients with hypertension or diabetes exam should be performed with pupils dilated
  • Quality of Life and Depression Assessment (SF-36V2, Beck Depression Inventory)
  • Functional status evaluation
  • Symptom assessment
  • HCV RNA
  • HCV Genotype
  • Urinalysis
  • Pregnancy Test
  • HIV Test
  • Other blood tests, including: complete blood count (CBC), International Normalized. Ratio (INR), Liver Panel, Creatine, Sodium Alpha-fetoprotein, triglycerides, iron studies, uric acid, thyroid stimulating hormone (TSH), antinuclear antibody (ANA)
  • Ultrasound (US), computed tomography (CT), and/or magnetic resonance imaging (MRI) (some or all are probably done in LDLT evaluation)

Week 0 (Randomization and/or Treatment Start)

  • Confirm eligibility
  • Initiate treatment for all genotype 2, 3 patients and genotype 1, 4, 5 or 6 patients randomized to treatment group
  • Repeat CBC, chemistries, INR

After randomization

  • Week 1 and 3: CBC (for treated patients only, may be performed in local labs)
  • Every 2 weeks up to 12 weeks: CBC, chemistries
  • Weeks 4 and 8: Focused physical exam (signs and symptoms of liver disease) vital signs, urinalysis and symptom assessment
  • Every 4 weeks from 12 to 48 weeks: Full physical exam and vital signs, urinalysis and symptom assessment, CBC, chemistries.
  • Every 12 weeks up to 48 weeks: INR, TSH, urine or serum pregnancy test female (treated subjects of childbearing capacity only)
  • At 12 Weeks: HCV RNA is measured. Patients without a 2-log or more drop in HCV RNA level are declared nonresponders and treatment is discontinued.
  • After 12 weeks: HCV RNA is measured every 12 weeks on treatment by quantitative tests.
  • At the time of LDLT or DDLT: CBC, INR, chemistries, quantitative and qualitative HCV RNA, Medications, adverse events (AE)
  • Blood samples will be collected at Treatment Weeks 4, 8, 12, 24, 48 and at time of transplantation for subsequent HCV RNA testing in a central lab
  • Quality of life (QOL) assessment at week 12, 24 and 48: Beck Depression Inventory (BDI) and SF-36V2
  • Patients who discontinue treatment early due to adverse events will be followed according to the study schedule until 12 months after transplant or 48 weeks after randomization.

Post-LT (LDLT or DDLT) Follow-up

  • Week 12, 24 and 52: CBC, INR, chemistries, HCV RNA by quantitative testing (part of A2ALL prospective study)
  • Week 12, 24 and 52: Full physical exam and vital signs, urinalysis and symptom assessment
  • Week 12: TSH and urine or serum pregnancy test (treated subjects of childbearing capacity only)
  • Week 12, 24 and 52: QOL Assessment (BDI, and SF-36V2)
  • Week 12 and 52: Liver Biopsy (part of A2ALL prospective study). Pathologists reading the 3 and 12 month biopsies will be blinded to the patients' clinical course and treatment.
  • Blood samples will be collected at Week 12, 24 and 52 for subsequent HCV RNA testing in a central laboratory

Follow-up of Patients completing 48 weeks of Treatment without Transplantation

  • Week 12, 24 and 48: CBC, INR, chemistries, HCV RNA by quantitative testing
  • Week 12, 24 and 48: Full physical exam and vital signs, urinalysis and symptom assessment
  • Week 12: TSH and urine or serum pregnancy test (treated subjects of childbearing capacity only)
  • Week 12, 24 and 48: QOL Assessment (BDI, and SF-36V2)
  • Blood samples will be collected at Week 12, 24 and 48 for subsequent HCV RNA testing in a central laboratory

NOTE: As a result of LADR Protocol Amendment III, patients with hepatocellular carcinoma (HCC) and tumor stage T2 awaiting DDLT are now eligible to participate in the LADR study. The following inclusion criteria was added:

• Candidates for DDLT who are listed for transplantation and meet United Network for Organ Sharing (UNOS) criteria for MELD upgrade for HCC

HCC DDLT candidates will not have their transplant delayed if a liver becomes available even if they have not completed 12 weeks of Rx.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hepatitis C
Intervention  ICMJE Drug: LADR Treatment

PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:

Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was <0.5 ug/kg, PEGIFN was permanently discontinued.

Other Names:
  • PEG-Intron; Rebetol
  • Low Accelerated Dosing Regimen
Study Arms  ICMJE
  • Experimental: LADR Treatment, Genotypes 1,4,6
    Subjects randomized to low accelerating dose regimen (LADR) treatment
    Intervention: Drug: LADR Treatment
  • No Intervention: Standard care
    Subjects randomized to Standard Care group, Genotypes 1,4,6
  • Experimental: LADR treatment, Genotypes 2,3
    Subjects randomized to low accelerating dose regimen (LADR) treatment.
    Intervention: Drug: LADR Treatment
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 17, 2010)
79
Original Enrollment  ICMJE
 (submitted: August 25, 2005)
150
Actual Study Completion Date  ICMJE December 2009
Actual Primary Completion Date December 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adult (18 or older)
  • LDLT candidate
  • HCV RNA positive
  • Expected time on treatment is at least 12 weeks
  • Candidates for DDLT who are listed for transplantation and meet UNOS criteria for MELD upgrade for HCC

Exclusion Criteria:

  • Severe cytopenia (polymorphonuclear (PMN) leukocytes < 750, OR hemoglobin [Hgb] < 10 g/dL, OR platelet count < 35,000/mm3)
  • Uncontrolled depression or psychiatric disease characterized by current symptoms of major depression or other psychiatric disease or increase in medication for major depression or other psychiatric disease within the past three months.
  • Uncontrolled cardiopulmonary disease characterized by myocardial infarction, coronary artery bypass graft surgery, Percutaneous coronary intervention, or unstable angina within the past three months.
  • Uncontrolled autoimmune disease characterized by current symptoms of autoimmune disease or increase in medications within the last three months.
  • Autoimmune hepatitis
  • Active substance abuse within 6 months of initiation of treatment
  • Known intolerance or serious adverse event during prior therapy with interferon or ribavirin
  • Prior nonresponse after at least 24 weeks of full dose treatment with peginterferon plus ribavirin
  • Laboratory Model for End-Stage Liver Disease (MELD) score >20. Patients with laboratory MELD score 21-25 may be enrolled if deemed appropriate by the site investigator
  • Serum creatinine >2.2 mg/dL
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00135798
Other Study ID Numbers  ICMJE A2ALL LADR Protocol 62498(IND)
U01DK062498 ( U.S. NIH Grant/Contract )
U01DK062536 ( U.S. NIH Grant/Contract )
U01DK062444 ( U.S. NIH Grant/Contract )
U01DK062467 ( U.S. NIH Grant/Contract )
U01DK062483 ( U.S. NIH Grant/Contract )
U01DK062484 ( U.S. NIH Grant/Contract )
U01DK062494 ( U.S. NIH Grant/Contract )
U01DK062496 ( U.S. NIH Grant/Contract )
U01DK062505 ( U.S. NIH Grant/Contract )
U01DK062531 ( U.S. NIH Grant/Contract )
CRADA through NIH-NIDDK ( Other Identifier: Schering-Plough )
CTA through NIH-NIDDK ( Other Identifier: Ortho-Biotech )
HRSA ( Other Identifier: Health Resources and Services Administration )
ASTS ( Other Identifier: American Society of Transplant Surgeons )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Averell Sherker, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study Sponsor  ICMJE National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators  ICMJE
  • Schering-Plough
  • Ortho Biotech Clinical Affairs, L.L.C.
Investigators  ICMJE
Study Chair: Gregory T. Everson, MD University of Colorado, Denver
Study Director: James Everhart, MD National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
PRS Account National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Verification Date April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP